

LEUKEMIA • LEUKEMIA • LEUKEMIA • LEUKEMIA • L
W1
LE915
Volume 18, Number 4
April 2004

LEUKEMIA

Normal and Malignant Hemopoiesis

www.nature.com/leu

Official Journal of the

Leukaemia Research Fund, UK

LEUKEMIA

The Journal of Normal and Malignant Hemopoiesis

EDITOR-IN-CHIEF

C Nicole Muller-Bérat Killmann MD

SECTION EDITORS

Apoptosis Editorial Network: E Solary, France; DE Johnson, USA;

JA McCubrey, USA

Biology of Gene Therapy: J Nolta, USA

Bone Marrow Transplantation and Myelodysplasias:

T de Witte, The Netherlands

Chronic Myeloid Leukemia: R Hehlmann, Germany

Clinical Studies (Adult Leukemias) J Rowe, Israel; X Thomas, France

CLL and B cell malignancies: M Albitar, USA

Immunophenotyping: MJ Borowitz, USA

Leukemogenomics: J Radich, USA; JA McCubrey, USA;

N Muller-Bérat Killmann

Lymphoma: H Tilly, France

Molecular Cytogenetics: R Berger, France; A Hagemeijer, Belgium

Molecular Targets for Therapy; Basic aspects and therapeutic implications: N Muller-Bérat, France in conjunction with JA McCubrey, USA;

DE Johnson, USA; JD Licht, USA; JP Marie, France.

Myeloma: RM Kyle, USA

New Cell Lines: H Drexler, Germany

Normal Hemopoiesis and Stem Cells:

RE Ploemacher, The Netherlands; P Quesenberry, USA

Pediatric Hemopathies: CH Pui, USA

Pharmacodynamics and Pharmacogenomics: WK Plunkett, USA

Sensitivity and Resistance to Therapy: JP Marie, France

Signal Transduction and Cytokines: JA McCubrey, USA

Transcriptional Control and Deregulation: JD Licht, USA

Virology: Z Berneman, Belgium

Clinical Trial Editorial Research Group

BM Camitta, USA; E Estey, USA; SJ Forman, USA; W Hiddemann, Germany;
R Larson, USA; R Ohno, Japan; CH Pui, USA; J Rowe, USA; M Tallman, USA

Biotechnical Methods Section Leukemia
Editors: JJM van Dongen, The Netherlands;
D Grimwade, UK; A Hochhaus, Germany

EDITORIAL BOARD

T Abe, Japan
BV Afanassiev, Russia
M Baccarani, Italy
MR Baer, USA
K Ballen, USA
J Bartek, Denmark
C Bastard, France
OA Bernard, France
F Bertrand, USA
J-Y Cahn, France
D Campana, USA
Chang-an Deng, China
Z Chen, China
Z-Z Chen, China
G Cohen, UK
N Cross, UK
A Cuneo, Italy
W Dalton, USA
Z Darzynkiewicz, USA
L Degos, France
H Dohner, Germany
JR Downing, USA
V Duronio, Canada
WE Evans, USA

P Fenaux, France
A Ferrando, USA
R Franklin, USA
R Furman, USA
JA Gabert, France
RC Gallo, USA
A Ganser, Germany
J Gil, Spain
S Grant, USA
A Gratwohl, Switzerland
G Grosveld, USA
U Gullberg, Sweden
C Harrison, UK
H Hasle, Denmark
H Hirai, Japan
O Hrusak, Czech Republic
U Jäger, Austria
C Jordan, USA
WM Kast, USA
TJ Kipps, USA
M Kneba, Germany
S Knuutila, Finland
M Lanotte, France
HJ Lawrence, USA

DC Linch, UK
T Lion, Austria
F Lo Coco, Italy
E Macintyre, France
JA Madrigal, UK
F Mandelli, Italy
E Matutes, UK
EA McCulloch, Canada
A Melnick, USA
D Metcalf, Australia
K Miyazawa, Japan
SD Mundle, USA
V Najfeld, USA
T Naoe, Japan
K Ohyashiki, Japan
D Olive, France
A Orfao, Spain
N Panoskaltzis, UK
J Pedersen-Bjergaard, Denmark
S Pemrick, USA
S Pileri, Italy
Y Pommier, USA
P Porcu, USA

A Rapoport, USA
S Raynaud, France
MV Relling, USA
D Ribatti, Italy
C Rosenfeld, USA
JD Rowley, USA
JE Rubnitz, USA
P Ruvolo, USA
D Scheinberg, USA
B Schlegelberger, Germany
M Schrappe, Germany
A Shimoni, Israel
R Siebert, Germany
P Sonneveld, The Netherlands
F Marc Stewart, USA
CA Stiller, UK
T Szczepanski, Poland
U Testa, Italy
R Van Etten, USA
C Verfaillie, USA
D Viswanatha, USA
D Weisdorf, USA
C Willman, USA

CONSULTANTS

Statistics: S Suci, Belgium
Liaison editor with Autoimmunology: A Wiik, Denmark
Liaison with Leukaemia Research Fund, UK, David Grant, Scientific Director

HONORARY MEMBERS

J Bernard, France
R Zittoun, France
J Freireich, USA
F Gavosto, Italy
D van Bekkum, The Netherlands
C Rozman, Spain
GE Francis, UK

OFFICIAL JOURNAL OF THE LEUKAEMIA RESEARCH FUND U.K.

LEUKEMIA

www.nature.com/leu

Leukemia is published by Nature Publishing Group, a division of Macmillan Publishers Ltd.

Scope *Leukemia* aims to provide a vehicle for all disciplines which directly or indirectly contribute to our understanding and treatment of leukemia, lymphoma and allied diseases. Studies on normal hemopoiesis are as important as those on leukemia because of their comparative relevance.

This journal is covered by Current Contents, SCIEExpanded, Research Alert, Current Contents Life Sciences EMBASE/Excerpta Medica, Current Advances in Cell and Developmental Biology, Index Medicus/Medline, Cambridge Scientific Abstracts, BIOSIS, Reference Update, Elsevier BIOBASE/Current Awareness in Biological Sciences, SUBIS, Current Advances in Genetics and Molecular Biology and SIIC.

Editorial Manuscripts (plus two copies) and all editorial correspondence should be sent to the Editor in Chief.

C Nicole Muller-Béart Killmann, MD, Editor in Chief

Leukemia, Hôpital St Louis, 1, Avenue Claude Vellefaux, 75475 Paris Cedex 10, France

Tel: +33 1 40 03 67 68/69

Fax: +33 1 42 49 40 85

E-mail: LeukemiaJournal@compuserve.com

Manuscripts should be submitted online at <http://www.mts-leu.nature.com>. Detailed instructions for authors are available at this website.

Publisher All business correspondence, and enquiries about supplement publication and sponsorship opportunities, should be addressed to *Leukemia*, Nature Publishing Group, Houndmills, Basingstoke, Hampshire RG21 6XS, UK. Tel: +44 1256 329242. Fax: +44 1256 810526.

Managing Editor: Michael Osuch

Executive Editor: Emma Greenwood

Production Controller: Mandy Webb

Leukemia is online at www.nature.com/leu

Visit the journal's home pages for details of the aims and scope, readership, instructions to authors and how to contact the Editor and publishing staff. Use the website to order a subscription, reprints, a sample copy or individual articles.

Free to all readers: tables of contents and abstracts for all articles published since 1997 and the complete text of the January 2004 issue. Register to receive the table of contents by e-mail as each issue is published.

Subscribers to the 2004 online version of the journal have access to PDF files of all articles since 1997. The full text of all articles in HTML format is also available from 2002.

Subscriptions—2004 Subscription Rates

INSTITUTIONAL SUBSCRIPTIONS

Combined (online plus print)

EU	£990/€1634
Rest of World	£990/US\$1584

Online only

EU	£891/€1470
Rest of World	£891/US\$1426

Site licences and institutional online access – for information on multi-user or multi-site access to Nature Publishing Group products please contact institutions@nature.com or telephone +44 20 7843 6426. For other enquiries please contact jsupport@nature.com or telephone +44 20 7843 4759.

PERSONAL SUBSCRIPTIONS

Combined (online plus print)

EU	£378/€624
Rest of World	£378/US\$605

Online only

EU	£340/€561
Rest of World	£340/US\$544

Prices for airmail delivery on application

Subscriptions – Outside the USA

Orders must be accompanied by remittance. Cheques should be made payable to Nature Publishing Group and sent to: The Subscription Department, Nature Publishing Group, Houndmills, Basingstoke, Hampshire RG21 6XS, UK. E-mail: subscriptions@nature.com Where appropriate, subscribers may make payments into UK Post Office Giro Account No: 519 2455. Full details must accompany the payment.

Subscriptions – USA

USA subscribers can call toll free: 1 800 747 3187. Please send/check/money order/credit card details to: The Subscription Department, Nature Publishing Group, Houndmills, Basingstoke, Hampshire RG21 6XS, UK. E-mail: subscriptions@nature.com

Prices are set in UK Sterling. Dollar prices are converted from UK Sterling at the current exchange rate. Accordingly, your credit card charge may vary slightly from the Dollar rate shown. To obtain the exact Dollar rate shown, please remit by check. All prices, specifications and details are subject to change without prior notification.

Advertising Enquiries concerning print and web advertising should be addressed to: David Bagshaw, Display Sales Executive, Nature Publishing Group, The Macmillan Building, 4 Crinan Street, London, N1 9XW, UK. Tel: +44 (0)20 7843 4610; Fax: +44 (0)20 7843 4725; E-mail: d.bagshaw@nature.com

Reprints and permissions For reprints of any article in this journal, please contact:

North America:

Lisa Vaccaro

E-mail: lvaccaro@natureny.com

Tel: +1 212 726 9233

Fax: +1 212 696 9591

Rest of World:

Christine Fothergill

E-mail: c.fothergill@nature.com

Tel: +44 (0) 20 7843 4967

Fax: +44 (0) 20 7843 4749

For reproduction rights, please contact:

Sophie Hooker

E-mail: s.hooker@nature.com; Tel: +44 (0) 20 7843 4893; Fax: +44 (0) 20 7843 4839

Leukemia (ISSN 0887-6924) is published monthly by Nature Publishing Group, c/o Mercury Airfreight International Ltd, 365 Blair Road, Avenel, NJ 07001, USA. Subscription price for institutions is \$1167 per annum. Periodicals postage paid at Rahway NJ. Postmaster: send address corrections to *Leukemia*, Nature Publishing Group, c/o Mercury Airfreight International Ltd, 365 Blair Road, Avenel, NJ 07001.

Copyright © 2004 Nature Publishing Group

ISSN 0887-6924

All rights of reproduction are reserved in respect of all papers, articles, illustrations, etc, published in this journal in all countries of the world.

All material published in this journal is protected by copyright, which covers exclusive rights to reproduce and distribute the material. No material published in this journal may be reproduced or stored on microfilm or in electronic, optical or magnetic form without the written authorisation of the publisher.

Authorisation to photocopy material for internal or personal use, or internal or personal use of specific clients, is granted by Nature Publishing Group to libraries and others registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided the relevant copyright fee is paid direct to CCC, 222 Rosewood Drive, Danvers, MA 01923, USA. Identification code for *Leukemia*: 0887-6924/04.

Apart from any fair dealing for the purposes of research or private study, or criticism or review, as permitted under the Copyright, Designs and Patent Act 1988, this publication may be reproduced, stored or transmitted, in any form or by any means, only with the prior permission in writing of the publishers, or in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency.

Whilst every effort is made by the publishers and editorial board to see that no inaccurate or misleading data, opinion or statement appears in this Journal, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Accordingly, the publishers and the Foundation, the editorial committee and their respective employees, offices and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement. Whilst every effort is made to ensure that drug doses and other quantities are presented accurately, readers are advised that new methods and techniques involving drug usage, and described

Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia

C Imai¹, K Mihara¹, M Andreansky¹, IC Nicholson², C-H Pui^{1,3,4}, TL Geiger³ and D Campana^{1,3,4}

¹Department of Hematology-Oncology, St Jude Children's Research Hospital, Memphis, TN, USA; ²Child Health Research Institute, Women's and Children's Hospital, Adelaide, South Australia; ³Department of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA; and ⁴Department of Pediatrics, University of Tennessee College of Medicine, Memphis, TN, USA

To develop a therapy for drug-resistant B-lineage acute lymphoblastic leukemia (ALL), we transduced T lymphocytes with anti-CD19 chimeric receptors, consisting of an anti-CD19 single-chain variable domain (reactive with most ALL cases), the hinge and transmembrane domains of CD8 α , and the signaling domain of CD3 ζ . We compared the antileukemic activity mediated by a novel receptor ('anti-CD19-BB- ζ ') containing the signaling domain of 4-1BB (CD137; a crucial molecule for T-cell antitumor activity) to that of a receptor lacking costimulatory molecules. Retroviral transduction produced efficient and durable receptor expression in human T cells. Lymphocytes expressing anti-CD19-BB- ζ receptors exerted powerful and specific cytotoxicity against ALL cells, which was superior to that of lymphocytes with receptors lacking 4-1BB. Anti-CD19-BB- ζ lymphocytes were remarkably effective in cocultures with bone marrow mesenchymal cells, and against leukemic cells from patients with drug-resistant ALL: as few as 1% anti-CD19-BB- ζ -transduced T cells eliminated most ALL cells within 5 days. These cells also expanded and produced interleukin-2 in response to ALL cells at much higher rates than those of lymphocytes expressing equivalent receptors lacking 4-1BB. We conclude that anti-CD19 chimeric receptors containing 4-1BB are a powerful new tool for T-cell therapy of B-lineage ALL and other CD19⁺ B-lymphoid malignancies.

Leukemia (2004) 18, 676–684. doi:10.1038/sj.leu.2403302
 Published online 12 February 2004

Keywords: T-cell receptor; CD137; acute lymphoblastic leukemia; B-cell lymphoma

Introduction

In approximately 20% of children and 65% of adults with acute lymphoblastic leukemia (ALL), drug-resistant leukemic cells survive intensive chemotherapy and cause disease recurrence.^{1,2} For patients with recurrent disease or with certain adverse disease features, such as B-lineage ALL with the t(9;22)(q34;q11), hypodiploidy <45 chromosomes, or *MLL* gene rearrangements in infants, current chemotherapy regimens are mostly ineffective.³ Significant improvements in cure rates require the development of treatments that bypass cellular mechanisms of drug resistance and that have high therapeutic indexes.

Clinical observations suggest that T lymphocytes can control the recurrence of chemotherapy-refractory leukemia. For example, T-cell-mediated graft-versus-host disease (GvHD) is associated with delay or suppression of leukemia relapse after allogeneic stem cell transplantation.^{4–6} Infusions of donor

lymphocytes can have antileukemic effects,^{7–10} but they carry the risk of severe GvHD and their antileukemic effect is often inadequate in ALL.^{8,11,12}

T-lymphocyte specificity can be redirected by the transduction of artificial immune receptors, which typically consist of an extracellular antibody-derived single-chain variable domain (scFv) and an intracellular signal transduction molecule (eg, CD3 ζ).^{13–15} Allogeneic or autologous T lymphocytes expressing these receptors can be activated by cell surface epitopes targeted by the scFv and kill the epitope-presenting cells. In ALL, CD19 is an attractive target because it is expressed on virtually all leukemic cells in around 85% of cases (ie, B-lineage ALL), it is not expressed by normal nonhematopoietic tissues, and among hematopoietic cells, it is only expressed by B-lineage lymphoid cells.^{16–19} However, CD3 ζ signaling may not be sufficient to produce a durable immune response; without a second signal, or costimulus, T cells rapidly undergo apoptosis after stimulation.^{19–22} This is a central issue for T-cell therapy of ALL because ALL cells generally lack the ligands of CD28,²³ and of 4-1BB (C Imai, D Campana, unpublished observations), the two major T-cell costimulatory molecules.

In this study, we compared the function of human T cells expressing an anti-CD19-CD3 ζ receptor to that of T cells expressing a novel chimeric receptor that contains the signal transduction domain of 4-1BB (CD137) as well as anti-CD19 scFv and CD3 ζ (anti-CD19-BB- ζ). 4-1BB, a tumor necrosis factor-receptor family member, was selected because it prevents activation-induced death of T cells,^{24–27} induces expansion of CD8⁺ cells,²⁸ and enhances CD8⁺ T-cell responses during viral infection and allograft rejection.^{28–31} Most importantly, extensive experimental evidence with animal models of cancer points to a crucial role of 4-1BB signaling for effective antitumor responses.^{32–36} We found that anti-CD19-BB- ζ -transduced T cells have powerful antileukemic activity: they can destroy CD19⁺ ALL cell lines and primary leukemic cells at low effector: target (E:T) ratios and under conditions that approximate the *in vivo* microenvironment where leukemic cells grow.

Materials and methods

Cells

The human B-lineage ALL cell lines OP-1 [t(9;22)(q34;q11)/*BCR-ABL*],³⁷ and RS4;11 [t(4;11)(q21;q23)/*MLL-AF4*],³⁸ the T-cell lines Jurkat³⁹ and CEM-C7,⁴⁰ and the myeloid cell lines K562⁴¹ and U-937⁴² were available in our laboratory. Cells were maintained in RPMI-1640 (Gibco, Grand Island, NY, USA) with 10% fetal calf serum (FCS; BioWhittaker, Walkersville, MD, USA) and antibiotics. Human adenocarcinoma HeLa cells and embryonic kidney fibroblast 293T cells were maintained in

Correspondence: Dr D Campana, Department of Hematology-Oncology, St Jude Children's Research Hospital, 332 North Lauderdale, Memphis TN 38105-2794, USA; Fax: +901-495 3749; E-mail: dario.campana@stjude.org

Primary leukemia cells were obtained from patients with newly diagnosed B-lineage ALL with the approval of the St Jude Children's Research Hospital Institutional Review Board and with appropriate informed consent. The diagnosis of B-lineage ALL was unequivocal; in each case, more than 95% of leukemic cells were positive for CD19. Peripheral blood samples were obtained from healthy adult donors. Mononuclear cells were collected from the samples by centrifugation on a Lymphoprep density step (Nycomed, Oslo, Norway) and were washed two times in phosphate-buffered saline (PBS) and once in AIM-V medium (Gibco).

Plasmids

The plasmid encoding anti-CD19 scFv was previously reported.⁴³ The pMSCV-IRES-GFP, pEQPAM3(-E), and pRDF were obtained from the St Jude Vector Development and Production Shared Resource. Signal peptide, hinge and transmembrane domain of CD8 α , and intracellular domains of 4-1BB, CD3 ζ , and CD19 were subcloned by PCR using a human spleen cDNA library (from Dr G Neale, St Jude Children's Research Hospital) as a template (Figure 1). We used splicing by overlapping extension by PCR (SOE-PCR) to assemble several genetic fragments.⁴⁴ The sequence of each genetic fragment was confirmed by direct sequencing. The expression cassettes were subcloned into *EcoRI* and *XhoI* sites of MSCV-IRES-GFP vector.

To transduce CD19-negative K562 cells with CD19, we constructed an MSCV-IRES-DsRed vector. The IRES and DsRed sequences were subcloned from MSCV-IRES-GFP and pDsRedN1 (Clontech, Palo Alto, CA, USA), respectively, and assembled by SOE-PCR. The IRES-DsRed cassette was digested and ligated into *XhoI* and *NotI* sites of MSCV-IRES-GFP. The expression cassette for CD19 was subsequently ligated into *EcoRI* and *XhoI* sites of MSCV-IRES-DsRed vector.

Virus production and gene transduction

To generate RD114-pseudotyped retrovirus, we used calcium phosphate DNA precipitation to transfect 3×10^6 293T cells, maintained in 10-cm tissue culture dishes (Falcon, Becton Dickinson, Franklin Lakes, NJ, USA) for 24 h, with 8 μ g of one of the vectors, anti-CD19- ζ , anti-CD19-BB- ζ , or anti-CD19-truncated, 8 μ g of pEQ-PAM3(-E), and 4 μ g of pRDF. After 24 h, the medium was replaced with RPMI-1640 with 10% FCS and antibiotics. Conditioned medium containing retrovirus was harvested 48 and 72 h after transfection, immediately frozen in dry ice, and stored at -80°C until use. HeLa cells were used to titrate virus concentration.

Peripheral blood mononuclear cells were incubated in a tissue culture dish for 2 h to remove adherent cells. Nonadherent

cells were collected and prestimulated for 48 h with 7 μ g/ml PHA-M (Sigma, St Louis, MO, USA) and 200 IU/ml human IL-2 (National Cancer Institute BRB Preclinical Repository, Rockville, MD, USA) in RPMI-1640 and 10% FCS. Cells were then transduced as follows. A 14-ml polypropylene centrifuge tube (Falcon) was coated with 0.5 ml of human fibronectin (Sigma) diluted to 100 μ g/ml for 2 h at room temperature and then incubated with 2% bovine serum albumin (Sigma) for 30 min. Prestimulated cells (2×10^5) were resuspended in the fibronectin-coated tube in 2–3 ml of virus-conditioned medium with polybrene (4 μ g/ml; Sigma) and centrifuged at 2400 g for 2 h. The multiplicity of infection (4–8) was identical in each experiment comparing the activity of different chimeric receptors. After centrifugation, cells were left undisturbed for 24 h in a humidified incubator at 37°C , 5% CO_2 . The transduction procedure was repeated on two successive days. Cells were then washed twice with RPMI-1640 and maintained in RPMI-1640, 10% FCS, and 200 IU/ml of IL-2 until use.

A similar procedure was used to express chimeric receptors in Jurkat cells, except that cells were not prestimulated. K562 cells expressing CD19 were created by resuspending 2×10^5 K562 cells in 3 ml of MSCV-CD19-IRES-DsRed virus medium with 4 μ g/ml polybrene in a fibronectin-coated tube; the tube was centrifuged at 2400 g for 2 h and left undisturbed in an incubator for 24 h. Control cells were transduced with the vector only. These procedures were repeated on 3 successive days. After confirming CD19 and DsRed expression, cells were subjected to single-cell sorting with a fluorescence-activated cell sorter (MoFlo, Cytomation, Fort Collins, CO, USA). The clones that showed the highest expression of DsRed and CD19 and of DsRed alone were selected for further experiments.


Detection of chimeric receptor expression

Cells were stained with goat anti-mouse (Fab)₂ polyclonal antibody conjugated with biotin (Jackson Immunoresearch, West Grove, PA, USA) followed by streptavidin conjugated to peridinin chlorophyll protein (PerCP; Becton Dickinson, San Jose, CA, USA). Anti-CD4 and anti-CD28 antibodies conjugated to PE and anti-CD8 conjugated to PerCP (from Becton Dickinson, and Pharmingen, San Diego, CA, USA) were also used. Antibody staining was detected with a FACScan flow cytometer (Becton Dickinson).

For Western blotting, 2×10^7 cells were lysed in 1 ml RIPA buffer (PBS, 1% Triton-X 100, 0.5% sodium deoxycholate, 0.1% SDS) containing 3 μ g/ml of pepstatin, 3 μ g/ml of leupeptin, 1 mM of PMSF, 2 mM of EDTA, and 5 μ g/ml of aprotinin. Cell lysates were separated by SDS-PAGE on a 12% acrylamide gel (BioRad, Hercules, CA, USA). After transfer to a PVDF membrane, this was incubated with a mouse anti-human CD3 ζ (clone 8D3; Pharmingen) and then with a goat anti-mouse IgG horseradish peroxidase-conjugated antibody. Antibody binding was revealed by using the ECL kit (Pharmacia, Piscataway, NJ, USA).

Expansion of receptor-transduced primary T cells and IL-2 production

Receptor-transduced lymphocytes (3×10^5) were cocultured with 1.5×10^5 irradiated OP-1 cells in RPMI-1640 with 10% FCS with or without exogenous IL-2. Cells were pulsed weekly with irradiated target cells at an E:T ratio of 2:1. Viable cells



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.